Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Study Phase : Preclinical
Recipient : Hovione
Deal Size : Undisclosed
Deal Type : Partnership
Hovione & Firstgene Partner on HCC Targeted Therapy
Details : Hovione will grant Firstgene an exclusive license to its proprietary novel targeted Adeno-Associated Virus (AAV)-Like particle technology for the treatment of HCC.
Product Name : Undisclosed
Product Type : Cell and Gene therapy
Upfront Cash : Undisclosed
May 06, 2025
Lead Product(s) : Undisclosed
Therapeutic Area : Oncology
Highest Development Status : Preclinical
Recipient : Hovione
Deal Size : Undisclosed
Deal Type : Partnership